Research
TRIM28-mediated SUMOylation of ERG at K389 conveys PARP inhibitor resistance by inhibiting 53BP1 expression in CRPC
Science · By Shiwei Liu, Zhe Hong, Zhongyuan Wang, Yongqing Zhang, Chenye Jiang, Yuchen Jiang, Runkai Zhang, Zheng Liu, Zhi Shang, Guowen Lin, Zongyuan Hong & Bo Dai ·
The Brief
- A study in Science Advances reports that TRIM28-mediated SUMOylation of ERG at lysine 389 confers PARP inhibitor resistance in castration-resistant prostate cancer (CRPC).
- The mechanism works by inhibiting 53BP1 expression.
- The paper was published in Science Advances, Volume 12, Issue 47, November 2026.
Why it matters
The findings identify a molecular pathway linked to resistance against PARP inhibitors in castration-resistant prostate cancer, which may inform future treatment strategies and biomarker research.
Who’s affected
- prostate cancer researchers
- oncologists and clinical researchers working on PARP inhibitors
- #prostate cancer
- #PARP inhibitors
- #drug resistance
- #SUMOylation
- #53BP1
Science Advances, Volume 12, Issue 47 , November 2026.